Sinopharm Group (1099) Fair Value & Analysis
Healthcare · HK · Market cap HK$49.6B
Fair value as of: Jul 5, 2026
From 24 valuation models · updated 15 days ago
Fair value updated Jul 5, 2026, revised from HK$135.40 to HK$61.33 (−54.7%) since Jul 2, 2026. Share price +9.6% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$15.52 – HK$20.90 · fair‑value band HK$45.99 – HK$76.66 · the HK$17.57 price screens below the HK$61.33 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sinopharm Group (1099) currently trades at HK$17.57, while our model-based Fair Value estimate is HK$61.33, implying the stock looks roughly 249.1% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Sinopharm Group generated revenue of HK$574B at a net margin of 1.2%. Revenue declined 0.6% year over year. It earns a return on equity of 8.1%. Net debt stands at HK$47.0B. Fundamentals as of Jul 5, 2026
Our scenario range runs from HK$45.99 (bear case) to HK$76.66 (bull case); at HK$17.57, the current price sits below that range. The share trades about 17% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 249%, 1099 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sinopharm Group reported revenue of HK$575B in FY2025 versus HK$521B in FY2021, a compound +2.5%/yr. Reported net income was HK$7.2B in FY2025, compounding −2.0%/yr from FY2021.
Is 1099 fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$999.49 | R$1,236 | +24% |
| Cencora, Inc COR | $270.32 | $168.24 | -38% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Henry Schein, Inc HSIC | $78.85 | $62.37 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥45.15 | +183% |
| Galenica AG GALNF | $115.00 | $97.98 | -15% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥20.81 | ¥25.18 | +21% |
| Medipal Holdings MEPDF | $18.35 | $23.62 | +29% |
| Jointown Pharmaceutical Group 600998 | ¥4.79 | ¥11.56 | +141% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sinopharm Group (1099) undervalued?
What is the fair value of 1099?
What is the quality score of 1099?
What is the revenue of Sinopharm Group (1099)?
What is the net profit margin of 1099?
Does Sinopharm Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Sinopharm Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.